Chugai up on Roche takeover rumor despite denial
This article was originally published in Scrip
Despite putting out a statement over the weekend denying it was in talks with Roche, shares of Japan's Chugai Pharmaceutical have risen to a record high following reports that the Swiss pharma giant wants to acquire the remainder of the company that it does not already own.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.